Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

ATNM Actinium Pharmaceuticals Inc

1,10

0,00 (0,00%)

Vor Marktöffnung

Zuletzt aktualisiert: 10:56:33

Verzögert um 15 Minuten

Form 3 - Initial statement of beneficial ownership of securities

Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
Von Feb 2025 bis Mär 2025

Click Here for more Actinium Pharmaceuticals Charts.

Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
Von Mär 2024 bis Mär 2025

Click Here for more Actinium Pharmaceuticals Charts.

News Actinium Pharmaceuticals Inc

Form 8-K - Current report
Mittwoch 27 November 2024 (3 Monate vor) • Edgar (US Regulatory)

Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024
Montag 18 November 2024 (4 Monate vor) • PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Donnerstag 14 November 2024 (4 Monate vor) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Samstag 9 November 2024 (4 Monate vor) • Edgar (US Regulatory)

Form ARS - Annual Report to Security Holders
Mittwoch 6 November 2024 (4 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 5 November 2024 (4 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 5 November 2024 (4 Monate vor) • Edgar (US Regulatory)

Form DEF 14A - Other definitive proxy statements
Dienstag 5 November 2024 (4 Monate vor) • Edgar (US Regulatory)

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
Montag 4 November 2024 (4 Monate vor) • PR Newswire (US)

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
Freitag 20 September 2024 (5 Monate vor) • PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Montag 5 August 2024 (7 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Montag 5 August 2024 (7 Monate vor) • Edgar (US Regulatory)

Weitere Actinium Pharmaceuticals Inc News-Artikel

Rush Enterprises

Palo Alto Networks

SPDR SSGA US Large Cap L...

BioXcel Therapeutics

Athabasca Minerals

Vontobel Financial Produ...

Global X Short Term US T...

XinFin Development Contract

CRSP US Technology Total...

Euronext France ESG Lead...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen